 |
市場調查報告書
商品編碼
1907931
癌症幹細胞市場：按癌症類型、產品類型、幹細胞來源、作用機制、應用、最終用戶和地區分類Cancer Stem Cells Market, By Cancer Type, By Product Type, By Stem Cell Source, By Mode of Action, By Application, By End User, By Geography |
||||||
據估計，癌症幹細胞市場在 2025 年的價值為 33.4 億美元，預計到 2032 年將達到 63.9 億美元，2025 年至 2032 年的複合年成長率為 9.7%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2024 | 市場規模（2025 年） | 33.4億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期（2025-2032 年）複合年成長率 | 9.70% | 預計金額（2032 年） | 63.9億美元 |
癌症幹細胞（CSCs）是腫瘤內一種獨特的細胞群，具有自我更新和分化成多種細胞譜系的能力，是腫瘤學研究和開發的重要標靶。它們能夠啟動腫瘤發生、促進轉移並導致治療抗藥性，因此在精準癌症醫學領域佔據核心地位。
全球癌症幹細胞市場涵蓋了一系列研究工具、治療方法和診斷解決方案，旨在識別、分離和標靶化這些難以捉摸的細胞群。該市場涉及多種癌症類型，包括乳癌、肺癌、大腸癌、腦腫瘤和骨髓惡性腫瘤，其應用範圍廣泛，涵蓋藥物研發、生物標記鑑定和個人化治療策略。對癌症幹細胞生物學的深入了解正在推動對流式細胞技術系統、細胞培養基、抗體和小分子抑制劑等專用技術的重大投資。
市場動態
全球癌症幹細胞市場受多種關鍵市場促進因素的推動，這些因素正在加速其擴張和技術進步。其中最主要的成長要素是全球癌症負擔的指數級成長。每年新增癌症病例超過1900萬例，因此迫切需要創新的治療方法來應對治療抗藥性和腫瘤復發問題。
政府機構、製藥公司和生物技術公司對癌症研究的大量投資顯著提高了癌症幹細胞（CSC）相關研究的資金籌措可能性。同時，在幹細胞生物學和癌症發病機制領域的突破性發現為藥物研發和個人化醫療開闢了新的途徑。單細胞定序、CRISPR基因編輯和先進的細胞分選系統等先進技術平台徹底改變了我們研究CSC的能力，使我們能夠更精確地識別和表徵這些細胞群。
然而，市場成長存在許多限制因素：專業實驗室設備和試劑的高成本限制了小規模研究機構和發展中地區的獲取；癌症幹細胞的稀有性和表現型可塑性給研究人員帶來了重大障礙，因為分離和表徵癌症幹細胞存在技術挑戰；針對癌症標靶治療的嚴格監管要求導致研發週期長、成本高。
儘管面臨這些挑戰，市場仍蘊藏著巨大的機遇，包括：開發用於早期癌症檢測和監測的液態生物檢體新應用；拓展對癌症幹細胞發揮關鍵作用的罕見癌症類型的研究；以及日益普及的3D細胞培養和類器官技術，這些技術能夠更真實地模擬體內腫瘤微環境。未來幾年，針對癌細胞和癌症幹細胞群的聯合治療日益受到重視，加上生物標記發現計畫投入的不斷增加，預計將推動市場持續成長和創新。
本報告的主要特點
- 本報告對全球癌症幹細胞市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模和複合年成長率，以 2024 年為基準年。
- 它還重點介紹了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的關鍵見解。
- 全球癌症幹細胞市場的主要企業將根據以下參數進行分析，例如公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使負責人和企業經營團隊能夠就未來的產品發布、合作關係、市場擴張和行銷策略做出明智的決策。
- 《全球癌症幹細胞市場》報告面向該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過用於分析全球癌症幹細胞市場的各種策略矩陣更輕鬆地做出決策。
目錄
第1章 分析目標與先決條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 影響分析
- 重大進展
- 監管情景
- 產品發布/核准
- PEST分析
- 波特五力分析
- 企業合併情景
- 產業趨勢
第4章 全球癌症幹細胞市場（依癌症類型分類）（2020-2032 年）
- 乳癌
- 血癌
- 肺癌
- 腦腫瘤
- 大腸直腸癌
- 胰臟癌
- 膀胱癌
- 肝癌
- 其他類型的癌症
第5章 全球癌症幹細胞市場（依產品類型分類）（2020-2032 年）
- 細胞培養產品
- 細胞分離產品
- 細胞分析產品
- 分子分析產品
- 其他輔助工具/試劑（例如，培養基、標記物、檢測試劑盒）
6. 全球癌症幹細胞市場（依幹細胞來源分類）（2020-2032 年）
- 骨髓來源
- 周邊血來源
- 臍帶血來源
- 誘導性多功能幹細胞（iPS細胞）
7. 全球癌症幹細胞市場依作用機制分類（2020-2032 年）
- 標靶癌症幹細胞療法
- 基於免疫療法的方法
- 其他（化療抗藥性逆轉劑）
第8章 全球癌症幹細胞市場按應用領域分類（2020-2032 年）
- 研究與開發
- 生物標記鑑定
- 藥物發現與篩檢
- 腫瘤發生研究
- 診斷用途
- 癌症預後
- 微量殘存疾病的檢測
- 治療應用
- 臨床治療
- 輔助性治療
9. 全球癌症幹細胞市場（按最終用戶分類）（2020-2032 年）
- 醫院、癌症治療中心
- 製藥和生物技術公司
- 學術和研究機構/研究機構
- 委外研發機構（CRO）
- 其他終端使用者（細胞庫、診斷中心）
第10章 全球癌症幹細胞市場（按地區分類）（2020-2032 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第11章 競爭格局
- Lineage Cell Therapeutics, Inc.
- FUJIFILM Irvine Scientific
- Thermo Fisher Scientific Inc.
- Merck KGaA
- MacroGenics, Inc.
- Miltenyi Biotec
- AbbVie Inc.
- STEMCELL Technologies Inc.
- Bionomics
- Sino Biological Inc.
- Celgene Corporation
- Incyte Corporation
- Novartis AG
- Pfizer Inc.
- Lonza Group AG
第12章 分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map (COM)
第13章 參考文獻與分析方法
- 參考
- 分析方法
- 關於 Coherent Market Insights
Cancer Stem Cells Market is estimated to be valued at USD 3.34 Bn in 2025 and is expected to reach USD 6.39 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.34 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.70% | 2032 Value Projection: | USD 6.39 Bn |
Cancer stem cells (CSCs) represent a unique subpopulation of cells within tumors that possess self-renewal capabilities and multilineage differentiation potential, making them critical targets in oncology research and therapeutic development. These cells are characterized by their ability to initiate tumor formation, drive metastasis, and contribute to treatment resistance, positioning them at the forefront of precision cancer medicine.
The global cancer stem cells market encompasses a comprehensive ecosystem of research tools, therapeutic agents, and diagnostic solutions designed to identify, isolate, and target these elusive cellular populations. This market spans various cancer types including breast, lung, colorectal, brain, and hematological malignancies, with applications extending across drug discovery, biomarker identification, and personalized treatment strategies. The increasing understanding of CSC biology has catalyzed significant investments in specialized technologies such as flow cytometry systems, cell culture media, antibodies, and small molecule inhibitors.
Market Dynamics
The global cancer stem cells market is propelled by several key drivers that collectively accelerate its expansion and technological advancement. The primary growth catalyst stems from the exponentially increasing global cancer burden, with over 19 million new cases diagnosed annually, creating urgent demand for innovative therapeutic approaches that address treatment resistance and tumor recurrence.
Substantial investments in cancer research by government agencies, pharmaceutical companies, and biotechnology firms have significantly enhanced funding availability for CSC-related studies, while breakthrough discoveries in stem cell biology and cancer pathogenesis have opened new avenues for drug development and personalized medicine approaches. Advanced technological platforms including single-cell sequencing, CRISPR gene editing, and sophisticated cell sorting systems have revolutionized CSC research capabilities, enabling more precise identification and characterization of these cellular populations.
However, market growth faces notable restraints including the high costs associated with specialized research equipment and reagents, which can limit accessibility for smaller research institutions and developing regions. Technical challenges in CSC isolation and characterization due to their rarity and phenotypic plasticity create significant barriers for researchers, while stringent regulatory requirements for CSC-targeting therapeutics extend development timelines and increase costs.
Despite these challenges, the market presents substantial opportunities through emerging applications in liquid biopsy development for early cancer detection and monitoring, expanding research into rare cancer types where CSCs play critical roles, and growing adoption of 3D cell culture and organoid technologies that better recapitulate in vivo tumor environments. The increasing focus on combination therapies targeting both bulk tumor cells and cancer stem cell populations, coupled with rising investments in biomarker discovery programs, positions the market for sustained growth and innovation in the coming years.
Key Features of the Study
- This report provides in-depth analysis of the global cancer stem cells market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cancer stem cells market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Lineage Cell Therapeutics, Inc., FUJIFILM Irvine Scientific, Thermo Fisher Scientific Inc., Merck KGaA, MacroGenics, Inc., Miltenyi Biotec, AbbVie Inc., STEMCELL Technologies Inc., Bionomics, Sino Biological Inc., Celgene Corporation, Incyte Corporation, Novartis AG, Pfizer Inc., and Lonza Group AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cancer stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer stem cells market
Market Segmentation
- Cancer Type Insights (Revenue, USD Bn, 2020 - 2032)
- Breast Cancer
- Blood Cancer
- Lung Cancer
- Brain Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Bladder Cancer
- Liver Cancer
- Other Cancer Types
- Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Cell culturing products
- Cell separation products
- Cell analysis products
- Molecular analysis products
- Other supporting tools/reagents (e.g. media, markers, assay kits)
- Stem-cell Source Insights (Revenue, USD Bn, 2020 - 2032)
- Bone Marrow-derived
- Peripheral Blood-derived
- Umbilical Cord Blood-derived
- Induced Pluripotent Stem Cells (iPSCs)
- Mode of Action Insights (Revenue, USD Bn, 2020 - 2032)
- Targeted Cancer Stem Cell Therapies
- Immunotherapy-based Approaches
- Others (Chemotherapy Resistance Reversal Agents)
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Research and Development
- Biomarker Identification
- Drug Discovery and Screening
- Tumorigenesis Studies
- Diagnostic Applications
- Cancer Prognosis
- Minimal Residual Disease Detection
- Therapeutic Applications
- Clinical Treatment
- Adjunct Therapy
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and cancer treatment centers
- Pharmaceutical and biotechnology companies
- Academic and research institutes/laboratories
- Contract research organizations (CROs)
- Other end users (Cell banks, diagnostic centers)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Lineage Cell Therapeutics, Inc.
- FUJIFILM Irvine Scientific
- Thermo Fisher Scientific Inc.
- Merck KGaA
- MacroGenics, Inc.
- Miltenyi Biotec
- AbbVie Inc.
- STEMCELL Technologies Inc.
- Bionomics
- Sino Biological Inc.
- Celgene Corporation
- Incyte Corporation
- Novartis AG
- Pfizer Inc.
- Lonza Group AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cancer Stem Cells Market, By Cancer Type
- Global Cancer Stem Cells Market, By Product Type
- Global Cancer Stem Cells Market, By Stem Cell Source
- Global Cancer Stem Cells Market, By Mode of Action
- Global Cancer Stem Cells Market, By Application
- Global Cancer Stem Cells Market, By End User
- Global Cancer Stem Cells Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Cancer Stem Cells Market, By Cancer Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Blood Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Brain Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liver Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Cancer Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Cancer Stem Cells Market, By Product Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Cell culturing products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cell separation products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cell analysis products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Molecular analysis products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other supporting tools/reagents (e.g. media, markers, assay kits)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Cancer Stem Cells Market, By Stem Cell Source, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Bone Marrow-derived
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Peripheral Blood-derived
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Umbilical Cord Blood-derived
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Induced Pluripotent Stem Cells (iPSCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Cancer Stem Cells Market, By Mode of Action, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Targeted Cancer Stem Cell Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Immunotherapy-based Approaches
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Chemotherapy Resistance Reversal Agents)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Cancer Stem Cells Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Research and Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biomarker Identification
- Drug Discovery and Screening
- Tumorigenesis Studies
- Diagnostic Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cancer Prognosis
- Minimal Residual Disease Detection
- Therapeutic Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Clinical Treatment
- Adjunct Therapy
9. Global Cancer Stem Cells Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and cancer treatment centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pharmaceutical and biotechnology companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Academic and research institutes/laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Contract research organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other end users (Cell banks, diagnostic centers)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Cancer Stem Cells Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Lineage Cell Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FUJIFILM Irvine Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MacroGenics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Miltenyi Biotec
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- STEMCELL Technologies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bionomics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sino Biological Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Incyte Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lonza Group AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
